Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial-Reference-Cited by-同舟云学术

Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial

Published:2021-11-23 Issue:1 Volume:48 Page:36-44
ISSN:0342-4642
Container-title:Intensive Care Medicine
language:en
Short-container-title:Intensive Care Med

Author:

Bellingan G.^ORCID,Jacono F.,Bannard-Smith J.,Brealey D.,Meyer N.,Thickett D.,Young D.,Bentley A.,McVerry B. J.,Wunderink R. G.,Doerschug K. C.,Summers C.,Rojas M.,Ting A.^ORCID,Jenkins E. D.

Funder

National Institute on Alcohol Abuse and Alcoholism

Innovate UK

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00134-021-06570-4.pdf

Reference33 articles.

1. Matthay MA, Zemans RL, Zimmerman GA et al (2019) Acute respiratory distress syndrome. Nat Rev Dis Primers 5(1):18. https://doi.org/10.1038/s41572-019-0069-0

2. Thompson BT, Chambers RC, Liu KD (2017) Acute respiratory distress syndrome. N Engl J Med 377(19):1904–1905. https://doi.org/10.1056/NEJMra1608077